Patients with advanced or metastatic neuroendocrine tumors that express somatostatin receptors are prime candidates for PRRT. Before undergoing therapy, patients usually undergo diagnostic imaging, such as a PET scan, to confirm the presence of these receptors. Additionally, candidates should have adequate renal and bone marrow function to tolerate the treatment.
